Smith & Nephew PLC header image

Smith & Nephew PLC

SNN

Equity

ISIN null / Valor 1111046

CTA NASDAQ OMX Stock Exchange (2026-11-09)
USD 31.05-0.32%

Smith & Nephew PLC
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Smith & Nephew PLC is a global medical technology company that develops and manufactures a wide range of clinical devices and solutions for orthopaedics, advanced wound management, sports medicine, and ear, nose, and throat (ENT) procedures. The company’s orthopaedics division produces implants for hip and knee joint replacements, along with trauma products designed to stabilize fractures and correct bone deformities, while also incorporating robotics-assisted technologies to support surgical precision. Its advanced wound management offerings cover a variety of products for treating both acute and chronic wounds, including conditions such as diabetic and pressure ulcers, burns, and post-operative complications. In addition, the sports medicine and ENT portfolios provide instruments and implants for minimally invasive soft tissue repairs and various ENT procedures. Overall, Smith & Nephew leverages these diversified capabilities to address a broad spectrum of clinical needs within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-6.56%1Y
27.7%3Y
-14.0%5Y

Performance

29.1%1Y
65.3%3Y
53.4%5Y

Volatility

Market cap

13192 M

Market cap (USD)

Daily traded volume (Shares)

1,335,403

Daily traded volume (Shares)

1 day high/low

24.76 / 24.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Cipla Ltd
Cipla Ltd Cipla Ltd Valor: 1850620
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.21%INR 1,406.00
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.52%GBP 16.25
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited Valor: 12029898
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%INR 1,905.00
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.06%EUR 67.40
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.32%SEK 496.60
Metropolis Healthcare Ltd.
Metropolis Healthcare Ltd. Metropolis Healthcare Ltd. Valor: 11536062
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.20%INR 581.80
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Valor: 2593348
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.95%INR 6,512.20
Lupin Limited
Lupin Limited Lupin Limited Valor: 11598960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.11%INR 2,012.00
Abbott India Limited
Abbott India Limited Abbott India Limited Valor: 561999
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.17%INR 26,648.25
Quest Diagnostics Inc
Quest Diagnostics Inc Quest Diagnostics Inc Valor: 566162
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.58%USD 259.67